Dashboard
Manage Tickers

RGLS Regulus Therapeutics Inc.

Nasdaq regulusrx.com


$ 0.00 $ 0.00 (0 %)    

Wednesday, 25-Jun-2025 00:00:00 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.07 $ 0.00 (0 %)
DIA $ 464.36 $ 0.00 (0 %)
SPY $ 667.27 $ 0.00 (0 %)
TLT $ 90.90 $ 0.00 (0 %)
GLD $ 389.22 $ 0.00 (0 %)
$ 8.16
$ 8.15
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 0.83 - $ 8.35
9,342,413
na
564.95M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2025 03-31-2025 10-Q
2 03-13-2025 12-31-2024 10-K
3 11-07-2024 09-30-2024 10-Q
4 08-08-2024 06-30-2024 10-Q
5 05-09-2024 03-31-2024 10-Q
6 03-21-2024 12-31-2023 10-K
7 11-09-2023 09-30-2023 10-Q
8 08-08-2023 06-30-2023 10-Q
9 05-11-2023 03-31-2023 10-Q
10 03-23-2023 12-31-2022 10-K
11 11-14-2022 09-30-2022 10-Q
12 08-11-2022 06-30-2022 10-Q
13 05-12-2022 03-31-2022 10-Q
14 03-10-2022 12-31-2021 10-K
15 11-10-2021 09-30-2021 10-Q
16 08-10-2021 06-30-2021 10-Q
17 05-14-2021 03-31-2021 10-Q
18 03-09-2021 12-31-2020 10-K
19 11-05-2020 09-30-2020 10-Q
20 08-13-2020 06-30-2020 10-Q
21 05-14-2020 03-31-2020 10-Q
22 03-12-2020 12-31-2019 10-K
23 11-12-2019 09-30-2019 10-Q
24 08-08-2019 06-30-2019 10-Q
25 05-10-2019 03-31-2019 10-Q
26 03-18-2019 12-31-2018 10-K
27 11-09-2018 09-30-2018 10-Q
28 08-09-2018 06-30-2018 10-Q
29 05-10-2018 03-31-2018 10-Q
30 03-08-2018 12-31-2017 10-K
31 11-08-2017 09-30-2017 10-Q
32 08-02-2017 06-30-2017 10-Q
33 05-05-2017 03-31-2017 10-Q
34 03-03-2017 12-31-2016 10-K
35 11-02-2016 09-30-2016 10-Q
36 08-03-2016 06-30-2016 10-Q
37 05-03-2016 03-31-2016 10-Q
38 02-23-2016 12-31-2015 10-K
39 11-06-2015 09-30-2015 10-Q
40 08-05-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Novartis Subsidiary Launches Offer to Acqu...
05/27/2025 12:16:45

regulus-therapeutics-q1-eps-015-beats-024-estimate
Regulus Therapeutics Q1 EPS $(0.15) Beats ...
05/08/2025 20:58:58

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of ...

this-parsons-analyst-is-no-longer-bullish-here-are-top-3-downgrades-for-thursday
This Parsons Analyst Is No Longer Bullish;...
05/01/2025 17:40:53

wells-fargo-downgrades-regulus-therapeutics-to-equal-weight-announces-9-price-target
Wells Fargo Downgrades Regulus Therapeutic...
05/01/2025 14:57:33

Wells Fargo analyst Yanan Zhu downgrades Regulus Therapeutics (NASDAQ:RGLS) from Overweight to Equal-Weight and announces $9...

jones-trading-downgrades-regulus-therapeutics-to-hold-lowers-price-target-to-7
Jones Trading Downgrades Regulus Therapeut...
04/30/2025 17:47:51

Jones Trading analyst Catherine Novack downgrades Regulus Therapeutics (NASDAQ:RGLS) from Buy to Hold and lowers the price t...

canaccord-genuity-downgrades-regulus-therapeutics-to-hold-lowers-price-target-to-11
Canaccord Genuity Downgrades Regulus Thera...
04/30/2025 17:45:35

Canaccord Genuity analyst Whitney Ijem downgrades Regulus Therapeutics (NASDAQ:RGLS) from Buy to Hold and lowers the price t...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/30/2025 17:05:40

crude-oil-falls-over-3-regulus-therapeutics-shares-spike-higher
Crude Oil Falls Over 3%; Regulus Therapeut...
04/30/2025 16:24:25

novartis-to-buy-us-kidney-drug-developer-regulus-therapeutics-for-around-800-million
Novartis To Buy US Kidney Drug Developer R...
04/30/2025 15:22:41

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to clos...

sp-500-falls-2-caterpillar-reports-downbeat-q1-results
S&P 500 Falls 2%; Caterpillar Reports Down...
04/30/2025 13:52:36

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
04/30/2025 12:07:52

trading-halt-halt-status-updated-at-72500-am-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:25:...
04/30/2025 11:25:09

Core News & Articles
Novartis To Buy Regulus Therapeutics For $...
04/30/2025 11:07:27

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative med...

trading-halt-halted-at-65500-am-et---trading-halt-halt-news-pending
Trading Halt: Halted at 6:55:00 a.m. ET - ...
04/30/2025 10:55:04

wells-fargo-upgrades-regulus-therapeutics-to-overweight-raises-price-target-to-6
Wells Fargo Upgrades Regulus Therapeutics ...
03/27/2025 18:06:17

Wells Fargo analyst Yanan Zhu upgrades Regulus Therapeutics (NASDAQ:RGLS) from Equal-Weight to Overweight and raises the pri...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
03/27/2025 17:05:46

regulus-therapeutics-stock-shoots-higher-after-positive-results-from-investigational-drug-for-rare-type-of-kidney-disease
Regulus Therapeutics Stock Shoots Higher A...
03/27/2025 16:59:04

Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
03/27/2025 12:05:52

regulus-therapeutics-announced-topline-results-from-all-patients-in-the-fourth-cohort-in-its-phase-1b-mad-study-of-farabursen-for-autosomal-dominant-polycystic-kidney-disease
Regulus Therapeutics Announced Topline Res...
03/27/2025 11:02:59

Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney e...

canaccord-genuity-maintains-buy-on-regulus-therapeutics-maintains-28-price-target
Canaccord Genuity Maintains Buy on Regulus...
03/17/2025 15:37:05

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and maintains $28 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION